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Background: The Space GlucoseControl system (SGC) is a nurse-driven, computer-assisted device for glycemic
control combining infusion pumps with the enhanced Model Predictive Control algorithm (B. Braun, Melsungen,
Germany). We aimed to investigate the performance of the SGC in medical critically ill patients.
Methods: Two open clinical investigations in tertiary centers in Graz, Austria and Zurich, Switzerland were
performed. Efficacy was assessed by percentage of time within the target range (4.4-8.3 mmol/L; primary end
point), mean blood glucose, and sampling interval. Safety was assessed by the number of hypoglycemic episodes
(≤2.2 mmol/L) and the percentage of time spent below this cutoff level. Usability was analyzed with a standardized
questionnaire given to involved nursing staff after the trial.
Results: Forty medical critically ill patients (age, 62 ± 15 years; body mass index, 30.0 ± 8.9 kg/m2; APACHE II score,
24.8 ± 5.4; 27 males; 8 with diabetes) were included for a period of 6.5 ± 3.7 days (n = 20 in each center). The
primary endpoint (time in target range 4.4 to 8.3 mmol/l) was reached in 88.3% ± 9.3 of the time and mean arterial
blood glucose was 6.7 ± 0.4 mmol/l. The sampling interval was 2.2 ± 0.4 hours. The mean daily insulin dose was
87.2 ± 64.6 IU. The adherence to the given insulin dose advice was high (98.2%). While the percentage of time
spent in a moderately hypoglycemic range (2.2 to 3.3 mmol/L) was low (0.07 ± 0.26% of the time), one severe
hypoglycemic episode (<2.2 mmol/L) occurred (2.5% of patients or 0.03% of glucose readings).
Conclusions: SGC is a safe and efficient method to control blood glucose in critically ill patients as assessed in two
European medical intensive care units.
Keywords: Tight glycemic control, Critical illness, Critically ill patients, Protocol, Computer-assisted glycemic control,
Insulin infusion protocol, Glucose control in intensive careBackground
Since more than a decade, glucose control (GC) has
been an important, yet laborious treatment goal in in-
tensive care. After the first reactions that followed the
landmark Leuven trial in 2001 [1] and led to the wide-
spread attempt to implement tight glycemic control
(TGC, target 4.4-6.1 mmol/L) in intensive care units
(ICUs) worldwide, enthusiasm rapidly tapered when it* Correspondence: karin.amrein@medunigraz.at
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unless otherwise stated.became clear that safe and efficient GC requires experi-
ence, time and appropriate training besides being time-
consuming and hard to achieve, even in the controlled
setting of clinical trials.
Poor glycemic control - represented by hyperglycemia,
hypoglycemia and high variability - is strongly and con-
sistently associated with poor clinical outcomes [2-5], al-
though the effect seems to be attenuated in patients
with diabetes [5,6]. In one of the largest observational
databases reported to date, Badawi and colleagues dem-
onstrated in almost 200,000 critically ill patients that
mortality was lowest in a blood glucose range between
4.4-6.1 mmol/L and progressively increased with severityLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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higher variability [7]. However, due to the high risk of
hypoglycemia, this target range is no longer universally
recommended and guidelines currently advocate less
strict glycemic control in the setting of critical illness
and perioperative care [8-13]. It seems reasonable to at
least prevent severe hyperglycemia (>10 mmol/L) [14]
that may lead to glucosuria and fluid dysbalance.
High-quality GC can best be achieved with a protocol
combining continuous intravenous insulin with frequent
blood glucose measurements. In the last decade, most
ICUs have implemented nurse-based protocols, but their
use is often restricted by their complexity and the inabil-
ity to accurately account for changes in nutrition, an
established risk factor for the occurrence of hypoglycemic
episodes [15]. Computer-assisted GC may be able to over-
come some of the difficulties encountered in daily routine
and appears to be superior to standard care [16-21]. In the
hope of improving the quality of GC and reducing work-
load, several algorithms have been developed. The en-
hanced Model Predictive Control (eMPC) algorithm has
been studied in several clinical trials where it was found to
be efficient and safe [22-27]. It is now implemented in the
CE-certified Space GlucoseControl (SGC; B. Braun,
Melsungen, Germany) which was the first device on the
market available for routine use. We therefore aimed to
test this nurse-driven device in two medical intensive care
units (ICUs). The primary objective was to investigate the
efficacy of the system defined as time in target range using
a broader target range of 4.4-8.3 mmol/L for glucose con-
trol in medical ICU patients.
Methods
The study was performed as a non-controlled clinical
investigation in 40 medical critically ill patients at two
tertiary academic centers (Medical University of Graz,
Austria and the Medical University of Zurich, Switzerland).
The trial was registered at the Clinical Trials Data-
base (ClinicalTrials.gov Identifier: NCT01164423 and
NCT01164449). Selected data of the trial in Graz have
been published previously [28].
Informed consent procedure
Both institutional ethics committees (EC) approved the
trial before commencement, but the informed consent
procedure differed: at the Medical University of Graz,
the EC provided surrogate informed consent for study
inclusion. Patients who regained consciousness provided
written informed consent afterwards. At the Medical
University of Zurich, the relatives of the patient and one
physician uninvolved with routine treatment of the pa-
tient had to consent before any study-related activities.
The trial was conducted according to Declaration of
Helsinki and ISO 14155.Study population
Adult medical ICU patients assumed to stay ≥ 72 hours
at the ICU were screened for inclusion (>6.1 mmol/l or
already on insulin therapy) and exclusion criteria (insulin
allergy, presence of ketoacidosis, moribund patients
likely to die within 24 hours). All 40 screened patients
were enrolled and analyzed.
Target range and relevant variables for model prediction
The chosen target range for this trial was 4.4 - 8.3 mmol/l.
Variables included in the individualized model prediction
of insulin resistance are body weight, glucose concentra-
tion, administered insulin and carbohydrates (via enteral
and parenteral nutrition).
Definition of hypoglycemia
Severe hypoglycemia was defined as < 2.2 mmol/l and
moderate hypoglycemia as < 3.3 mmol/l.
SGC system and eMPC algorithm: training and
maintenance
The B. Braun Space GlucoseControl system (SGC) was
run at the bedside by the ICU nurses. SGC consists of
three infusion pumps, two for enteral and parenteral nu-
trition (B. Braun Infusomat® Space) and one for insulin
(B. Braun Perfusor® Space). The pumps are intercon-
nected via the Space Station that allows data communi-
cation between the pumps and the central user interface,
a touchscreen (SpaceControl) attached to the insulin
pump. The eMPC algorithm is implemented in the SGC
Module attached to and controlled by SpaceControl.
The handling of the eMPC algorithm has been described
in detail previously [25,29]. In brief, SGC gives an alarm
that the suggested time to the next sample has elapsed.
A nurse then measures and enters a current blood glu-
cose value in order to receive an advice regarding insulin
dose and time for the next glucose measurement (be-
tween 30 and 240 minutes). The advised insulin dose
rate has to be confirmed and is then set automatically at
the pump. Changes in enteral and parenteral nutrition
are directly communicated to the eMPC by the respect-
ive pumps that are part of SGC. Changes in nutrition
automatically lead to an adopted insulin dose rate pro-
posal. The system also stores all data on therapy, dis-
plays these data and trends all relevant information on
the user interface. In the last decade, various institutions
across Europe have actively participated in several trials
using the eMPC algorithm in a laptop computer version
and a prototype version of the SGC system [22-27,30,31].
Based on the results of these studies in different environ-
ments, changes were implemented in the algorithm.
The pumps used in SGC are the same as in routine
use at the Medical University Graz (B. Braun Infusomat®
and Perfusor® Space), while the Medical University
Table 1 Demographic and clinical characteristis of the
study population in Zurich (n = 20)
Demographic characteristics
Male (n/%) 13 (65%)
Age (yrs) 60.2 ± 14.3
Body mass index (kg/m2) 29.0 ± 6.6
APACHE II 24.2 ± 4.5
Clinical characteristics (n)






Mechanically ventilated 17 (85%)
Vasopressor therapy Norepinephrine: 11 (55%)
Dobutamine: 4 (20%)
Renal replacement therapy 4 (20%)
Steroid treatment 6 (30%)
Parenteral nutrition 6 (30%)
Enteral nutrition 18 (90%)
History of diabetes 4 (20%)
Patients on insulin before study start 18 (90%)
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at the latter site was more extensive. In Graz, all actively
participating nurses attended a structured one-on-one
training on virtual patients before enrolment of the first
patient o familiarize with the handling of the complete
SGC system. In Zurich, during daytime the device was
handled by a dedicated study nurse who also briefly
trained routine nursing staff for SGC use during other
times.
All trial related activities were carried out until referral
to the general ward, loss of the arterial line, end of iv in-
sulin need or after 14 treatment days. After termination
of the study, all patients were followed up for one week.
Glucose measurements were performed using an arterial
line available for routine monitoring purposes. Glucose
measurements were performed with a certified device
for glucose measurement in the ICU (Graz: Accu-Check
Inform, Roche Diagnostics GmbH, Mannheim, Germany;
Zurich: Accu-Check Aviva®, Roche Diagnostics GmbH,
Mannheim, Germany).
For intravenous insulin infusion, insulin aspart (Novorapid,
Novo Nordisk, Baegsvard, Denmark) was used in Graz
and recombinant human insulin (Actrapid, Novo Nordisk,
Baegsvard, Denmark) was used in Zurich. After study
completion, we asked the ICU nursing staff to fill in a
questionnaire on user acceptance of SGC.Hospital mortality 6 (30%)
Data are given as numbers (n) or means ± SD as appropriate. Baseline
data of the study population in Graz have been reported previously [28].
There are no significant differences between both populations with the
exception of a higher rate of norepinephrine use (90 vs. 55%, P < 0.01)
and a higher rate of parenteral nutrition in Graz 85 vs. 30%, P < 0.01.Statistical analysis
Statistical analysis was performed on an intention to treat
basis. Blood glucose values were linearly interpolated. The
percentage of time within the predefined glucose the tar-
get range (4.4-8.3 mmol/l) was defined as primary end-
point for the assessment of glucose control. Data are
reported as mean ± SD if not otherwise indicated. Data
analysis was performed using SPSS® version 19.0.Results
Study population and concomitant treatment
40 medical critically ill patients were included from
February 2010 to August 2011 (Graz February to December
2010, Zurich August 2010 to August 2011). Up to four pa-
tients were treated with SGC systems simultaneously at
each site. Baseline characteristics of the Zurich population
(n = 20) are given in Table 1. Baseline characteristics of
the Graz population have been reported previously [28]
and are similar except for a higher rate of norepinephrine
and parenteral nutrition. Because of substantial national
differences in informed consent procedure for patients
unable to give consent at the time of study inclusion,
time from ICU admission to study inclusion was signifi-
cantly different between the two sites (Graz 1.7 ± 1.5,
Zurich 6.7 ± 5.9 days, P = 0.001). Before study start, blood
glucose was controlled using the standard protocol.Protocol adherence, glucose control and sampling
frequency
No major protocol violations occurred. Overall, the pri-
mary endpoint (time in target range 4.4 to 8.3 mmol/l)
was reached in 83.4 ± 8.9% of the time in Graz and in
93.1 ± 7.1% in Zurich (p < 0.01). The mean glucose level
was not significantly different between both sites (6.8 ±
0.4 vs. 6.6 ± 0.4 mmol/l). At study start, the mean glucose
level was 9.4 ± 4.2 mmol/l (range: 4.8 to 26.3 mmol/l).
The daily number of glucose sampling varied from 8 to
19 times (12 ± 2) and the mean sampling interval per
day varied from 1.3 to 3.0 hours (2.2 ± 0.4). Detailed in-
formation regarding glucose readings and sampling
intervals within each center is given in Table 2. Per-
centages of time per day within blood glucose level
ranges with a focus on Zurich data are given in Table 3,
the detailed Graz data have been reported previously
[28]. Average and individual glucose profiles are dis-
played in Figure 1. Patients were included for 6.5 ±
3.7 days in the trial.
Table 2 Important details of glucose control and sampling interval during the study
Graz Zurich P Total
Blood glucose level at study start [mmol/l] 10.9 ± 5.3 8.0 ± 1.7 0.021 9.4 ± 4.2
Time from ICU admission to study start [days] 1.7 ± 1.5 6.7 ± 5.9 0.001 4.2 ± 4.9
Time to reach target range [hours] 5.3 ± 4.6 2.9 ± 2.3 0.157 4.7 ± 4.1
Sampling interval [hours] 2.0 ± 0.4 2.3 ± 0.4 0.013 2.2 ± 0.4
Mean BG level [mmol/l] 6.8 ± 0.4 6.6 ± 0.4 0.142 6.7 ± 0.4
< 3.3 mmol/l 0.03 ± 0.07 0.11 ± 0.37 0.297 0.07 ± 0.26
3.3-4.3 mmol/l 2.06 ± 1.83 0.47 ± 0.64 0.002 1.26 ± 1.57
4.4-8.3 mmol/l (target range) 83.4 ± 8.9 93.1 ± 7.1 0.060 88.3 ± 9.3
> 8.3 mmol/l 14.4 ± 16.7 7.6 ± 16.5 0.159 10.4 ± 8.5
Total study time [days] 7.0 ± 3.6 6.0 ± 3.8 0.389 6.5 ± 3.7
Data are given as mean± SD. Numbers for blood glucose ranges refer to percentage of time within the given range, boldface numbers give the results for the target range.
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6 of 40 patients (15%) experienced hypoglycemia (<3.3
mmol/l), this corresponded to 0.2% (6 out of 3044) of all
measurements. The percentage of time within 2.2 and
3.3 mmol/l was low (0.07 ± 0.26%). One severe hypo-
glycemic episode (2.1 mmol/l) occurred during the trial,
corresponding to 0.03% of all measurements or 2.5% of.all
patients. In the previously stable patient, the blood glucose
was at 6.5 mmol/l. SGC advised to continue the insulin
rate of 6.4 U/h and to measure blood glucose again after
4 hours. After 90 minutes, the nurse measured blood glu-
cose which was 4.5 mmol/l, but did not enter it into the
SGC system. At the proposed time, the blood glucose of
the patient was 2.1 mmol/l. The affected patient had been
mostly within target range for 3 days before this incident,
but after the insulin requirement was remarkably lower.
No relevant nutrition changes were undertaken during
this period.
Insulin and nutrition
Daily average insulin requirement was 87.2 ± 64.6 IU
(range: 18 to 360 IU). Virtually all patients received enteralTable 3 Glucose control for individual study days with a focu
Study day n Percentage of time [%]
<3.3 mmol/l 3
1 20 0.33 ± 1.50 0
2 18 0 0
3 18 0 0
4 15 0.5 ± 1.8 0
5 and later 13 0 1
Total both sites 40 0.07 ± 0.26 1
Total Graz 20 0.03 ± 0.07 2
Total Zurich 20 0.11 ± 0.37 0
Data are given as means ± SD. Detailed data of the study population in Graz have beenutrition via continuous infusion (38 of 40; 95%) and the
majority also received parenteral feeding (23 of 40; 57.5%).
User interventions and usability
The adherence to the given insulin dose advice was high
(98.2%). Out of 3285 eMPC advices, the user overruled
in 59 (1.8%) times: in 54 cases downwards (1.64%) and 5
times upwards (0.15%). There was no significant differ-
ence between the study sites. The magnitude of devia-
tions ranged from 0.1 to 18.0 IU insulin/hour and the
major reasons for overruling included small or large
changes in the advised insulin dose (e.g. ICU nurses set
a rate of or 0.0 IU instead of 0.6, or 5 IU insulin/hour in-
stead of proposed 15) and simply feeling uneasy with the
proposed insulin rate. The sampling time was excellently
followed.
At the end of the study, the nursing staff was asked to
complete a questionnaire regarding the usability of SGC.
51 of 100 involved nurses returned the questionnaire
(18/64 or 28% in Zurich, 31/46 or 67% in Graz).
There were significant differences in the subjective
judgement between the two centers, as the nursing staffs on Zurich data
.3-4.3 mmol/l 4.4-8.3 mmol/l >8.3 mmol/l
(Target range)
.9 ± 3.0 91.6 ± 10.6 7.2 ± 10.5
94.6 ± 8.0 5.4 ± 8.0
.1 ± 0.5 92.3 ± 16.5 7.6 ± 16.5
.8 ± 2.2 91.4 ± 12.5 7.3 ± 11.8
.2 ± 2.8 94.5 ± 5.7 4.3 ± 5.3
.3 ± 1.6 88.3 ± 9.3 10.4 ± 8.5
.1 ± 1.8 83.4 ± 8.9 14.5 ± 8.3
.5 ± 0.6 93.1 ± 7.1 6.3 ± 6.6




















no.of patients in the study
40 35 30        25 20 15 10 5
Figure 1 Average (bold line) and individual (thin lines) glucose profiles. Dashed lines mark the target range 4.4–8.3 mmol/L. Blue lines are
Zurich data, green lines are Graz data. The peak on day 7 (33 mmol/L) was caused by treatment for acute hyperkalemia with a 20% dextrose bolus.
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more favorably than in Zurich (Table 4).
Discussion
The debate about ideal glycemic control in intensive
care continues. In the last years, large intervention stud-
ies including the NICE-SUGAR trial unexpectedly failed
to replicate the initial and very promising finding of the
first Leuven study showing a significant survival benefit
for TGC in surgical ICU patients [1,32,33]. Substantial
differences between these studies were present in study
design, execution of glucose control and treated popula-
tion. Likely one of the main reasons why clinical trials
and meta-analyses showed negative results for TGC was
the high incidence of hypoglycemia induced by intensive
insulin therapy. Probably it was impossible to prevent
this because no reliable tool facilitating GC was avail-
able. The used (paper-based) protocol was often not ex-
tensively tested before implementation, and adherence
to it was not reported or registered, a fact that may be
especially problematic in a multi-center approach where
different sites often display substantial differences in
standards of critical care including important aspects in
nutrition and glycemic control. Despite all efforts, alarge gap is still evident between what is achievable and
what is desirable in glucose control – (near) normogly-
cemia besides minimal variability [34].
SGC with the implemented eMPC algorithm is a well-
validated, CE-certified nurse-driven tool to assist glucose
control in critical care. As demonstrated in our two cen-
ters, it was possible to achieve excellent adherence and
glycemic control with low variability. The target range of
4.4 to 8.3 mmol/l could be achieved in 83% (Graz) and
93% (Zurich) of the time. Despite excellent efficacy, us-
ability and performance parameters were assessed very
differently by the nursing staff at the two study sites. In
Zurich, glucose control was outstanding and significantly
better than in Graz, yet the involved ICU staff turned
out to be unsatisfied. We hypothesize that this difference
was caused by 1) the intensive hands-on simulated train-
ing performed only in Graz and 2) the long lasting rou-
tine use of BBraun pumps at the same site. Although the
training was a time-consuming and laborious process, it
nevertheless seems to be necessary when implementing
such a new tool in order to assure long-term functional-
ity and operator satisfaction within the ICU team. The
fact that infusion pumps from another manufacturer are
in use in Zurich meant that ICU staff needed to become
Table 4 Questionnaire results
Questionnaire, answers in favour
of Space TGC
Total (N = 51) Graz (N = 33) Zürich (N = 18) P
Number Rate Number Rate Number Rate
1: Performance (“good” or “excellent”) 35 68.6% 27 81.8% 8 44.4% 0.011
2: Reduction of workload 12 23.5% 11 33.3% 1 5.6% 0.037
3: Efficacy 33 64.7% 31 93.9% 2 11.1% < 0.001
4: User friendlyness 34 66.7% 30 90.9% 4 22.2% < 0.001
5: Problems in use 29 56.9% 24 72.7% 5 27.8% 0.003
6: Confidence 35 68.6% 29 87.9% 6 33.3% < 0.001
7: Prevention of mistakes 33 64.7% 28 84.8% 5 27.8% < 0.001
8: Routine use 25 49.0% 23 69.7% 2 11.1% < 0.001
9: Reliability (“complete trust”) 23 45.1% 21 63.6% 2 11.1% < 0.001
Nursing staff at both sites was asked to complete a questionnaire after recruitment had finished. These were the original formulations:
1. “How well was the patient’s blood glucose stabilised in the target range from 4.4 and 8.3 mmol/l?”
2. “Was your workload using Space TGC System reduced or increased?”
3. “Do you think that control of the patient’s blood glucose was maintained more effectively by the use of the Space TGC system compared with normal practice?”
4. “Is the Space TGC system user friendly?”
5. “Were there any problems with the use of the Space TGC system?”
6. “Did you feel confident using the Space TGC system?”
7. “Do you think that using the Space TGC system can help to avoid making mistakes when controlling the blood glucose?”
8. “Do you think that the Space TGC system may be a worthwhile tool for routine use in the ICU?”
9. “Did you trust the Space TGC system would maintain the blood glucose at a safe level?”
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dle two different types of pumps at the same time. This
is particularly evident in the response to question 8 re-
garding potential routine use which was viewed favor-
ably by 70% of nurses in Graz, but only 11% in Zurich.
Workload was perceived to be increased by the major-
ity of the users which is explainable by the relatively
frequent sampling and high documentation effort com-
pared to current routine care at both sites.
With regard to safety, one patient experienced severe
hypoglycemia (2.5% of patients or 0.03% of glucose read-
ings) which seems an acceptable rate in this population.
This incident was primarily attributable to a long (4-
hour) measurement interval that was suggested by the
device. However, although the responsible nurse felt un-
easy and measured a dropping blood glucose level of
4.5 mmol/l, it was not entered in the SGC and insulin
infusion continued with the same rate. With more ex-
tensive training of the involved staff, this hypoglycemic
episode may have been prevented as the eMPC almost
certainly would have advised to stop insulin infusion in
view of a rapidly falling blood glucose concentration.
The continued use of insulin at a glucose level below
5.6 mmol/l has recently been identified as one of the
most common causes for hypoglycemia in an analysis of
> 55,000 glucose readings in 1,657 patients [17]. This in-
cident also demonstrates that the possibility of user
overruling may be crucial for optimal SGC use and the
device’s suggestions should only be followed in view of
the clinical context.
Obviously, our study is limited by its small sample size
and open design. However, the primary aim was to indetail evaluate the complete SGC system in a medical
population of critically ill patients at two different sites.
As demonstrated by the individual profiles of the partici-
pants, glucose control could be established and main-
tained over the whole study period in both centers.
Another limitation is the use of bedside glucometers as
they were originally developed for glucose measurement
in another setting and are not accurate enough for gly-
cemic control in critically ill patients, especially when
anemia is present [35,36]. Morever, the mean sampling
interval of > 2 hours is a potential limitation as in com-
parison with continuous glucose monitoring, hypo- and
hyperglycemic excursions of blood glucose may have
been missed, as also described in the literature [37]. Cer-
tainly, our observations need to be confirmed in larger
populations with a focus on presence or absence of dia-
betes and also in a setting with CGM.
Under clinical trial conditions, subcutaneous continu-
ous glucose monitoring (CGM) has been found to be
sufficiently accurate when compared to arterial sampling
[38]. In a small pilot study, Kopecky and colleagues
showed that combining the eMPC algorithm with CGM
is a feasible method for glycemic control in cardiac sur-
gery patients [39]. Okabayashi et al. could demonstrate a
reduced risk for surgical site infections and excellent
perioperative tight glycemic control without hypoglycemic
episodes using a closed loop glycemic control system
with CGM in patients requiring hepato-biliary-pancreatic
surgery [40].
These studies and ours are important steps on the way
to the artificial pancreas at the bedside of the ICU pa-
tient - a real closed loop system that would ideally
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semi-automated method to improve glycemic control
and reduce workload [41]. Major efforts are also being
undertaken to internationally standardize important as-
pects of glycemic control, as evident in the 2013 Con-
sensus recommendations jointly written by the leading
experts in the field [42]. These developments will cer-
tainly greatly contribute in the implementation of safe,
efficient and not overly elaborate glucose control in crit-
ical care.Conclusions
SGC is a reliable and efficient computerized method for
glycemic control in the ICU. We suggest that SGC may
be a useful tool to aid in routine glycemic control and
reduce disparities in standards of care when performing
future multicenter clinical trials. Such trials are without
doubt necessary to address important details in the
blood glucose management of critically ill patients, such
as the use of individualized target ranges for different
patient populations, especially for diabetics versus non-
diabetics [43]. However, our experience indicates that
extensive training before implementation of such a tool
is crucial in order to ascertain the compliance of opera-
tors and to minimize hypoglycemic events.Competing interests
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